Discovery platform

V.HEART Discovery
Cardiac Safety Prediction

De-risk your pipeline by discarding unsafe molecules early on, with QT prolongation predictions: a mechanistic, CiPA-aligned complement to hERG and TQT studies.

Request demo

Cardiac Safety Predictions: QT prolongation prediction

How Discovery works

Candidate selection with human QT prolongation

Ingest
assay data

Input heart ion channel measurements
of your candidates

Profile
proarrhythmic risk

Predict human QT prolongation
and arrhythmic cases

Discard
unsafe candidates

Compare, identify and
discard unsafe candidates

Key benefits

How can V.HEART Discovery help you?

Discard unsafe candidates early,
with confidence

Exploit the benefits of cardiac safety predictions.
Use QT Prolongation predictions to anticipate the risk of your compounds at an early stage and decide which candidates are worth further exploration.

Cardiac-Safety-Prediction-discard-molecules

Explore the whole space of IC50 and H combinations

Characterise compounds from ion-channel IC50/H values or probability distributions, following the CiPA paradigm, and toggle between saline-buffer and plasma to account for environmental shifts.

cardiac-safety-predictions-Characterise-compounds

Study the effect on QT Prolongation from 0 to 50 Cmax and beyond

Get cardiac safety prediction across the full concentration range (0–50× Cmax and beyond) and protein-binding conditions, including overdose and abuse edge cases you cannot study in humans.

Cardiac safety predictions - computational toxicology predictions

Obtain sex-specific proarrhythmic potential

Understand the risk profile of your compounds:
Assess sex-specific proarrhythmic risk QT and arrhythmia predictions for all channel measurement combinations, capturing a known driver of TdP risk.

cardiac safety predictions - sex-specific analysis

Take it from Discovery to Development

Validate promising candidates with V.HEART Trials

Check Trials

Avoid changing the study model between pipeline stages.
Simulate your promising compounds with V.HEART Trials to get granular around different virtual patient populations.

Discard unsafe molecules

Simulate your promising compounds

Take full control over the population of interest

What we offer

Discover what V.HEART Discovery delivers

Leverage cardiac safety prediction and discard unsafe molecules early on

cardiac safety predictions - arrhythmic case

First arrhythmic cases

cardiac safety predictions - compounds combinations

Combinations that produce min/max ΔQT

cardiac safety predictions QT-response-analysis

QT response analysis by sex

cardiac safety predictions concentration-range

Concentration range for ΔQT of 10ms

Behind ELEM Cardiac Safety Prediction Platform

How does our technology work?

Digital Twins for Value-driven Healthcare

ELEM’s technology combines patient-specific data, high-performance physics-based simulation, and advanced computational modeling to create Virtual Human Twins.

Integrating in your pipeline cardiac safety prediction, opens the door to faster, safer, and data-driven early clinical decisions.

Check ELEM Technology

V.HEART Discovery Cardiac Safety Prediction